| Outcome | Total Comparisons/Studies | All Studies | Oxybutynin ER | Solifenacin | Total Studies | Oxybutynin ER | Total Studies | Fesoterodine |
|---|---|---|---|---|---|---|---|---|
| RR (95% CI) | RR (95% CI)[44] | RR (95% CI)[48] | RR (95% CI)[41] | RR (95% CI)[50] | ||||
|
| ||||||||
| Versus Oxybutynin IR | Versus Tolterodine IR | Versus Tolterodine ER | ||||||
| a Gastrointestinal AEs | 2 | 2.65 (0.75–9.28) | 2.37 (0.51–10.91) | 3.33 (0.37–30.16) | 1 | 2.94 (0.60–14.52) | 0 | -- |
| b Ocular/Visual AEs | 1 | 0.22 (0.01–4.42) | -- | 0.22 (0.01–4.42) | 1 | 5.87 (0.29–119.44) | 0 | -- |
| c Pain-related AEs | 1† (0) | -- | -- | † | 0 | -- | 0 | -- |
| d Cardiac AEs | 0 | -- | -- | -- | 0 | -- | 0 | -- |
| e Falls | 1 | 9.96 (0.56–176.92) | -- | 9.96 (0.56–176.92) | 1 | 8.21 (0.43–155.33) | 0 | -- |
| f Respiratory tract-related AEs | 1 | 0.56 (0.05–5.79) | -- | 0.56 (0.05–5.79) | 0 | -- | 1 | 0.54 (0.18–1.56) |
| g Neurological/Cognitive AEs | 1 | 0.56 (0.05–5.79) | -- | 0.56 (0.05–5.79) | 1 | 1.18 (0.17–8.06) | 1 | 5.37 (0.26–111.51) |
| h Nasal AEs | 1 | 0.07 (0.00–1.23) | -- | 0.07 (0.00–1.23) | 0 | -- | 0 | -- |
= I2 >25%;
=Adverse Event noted in Study but 0 count, AEs = Adverse Events; CI = confidence intervals; ER = extended release; IR = immediate release; RR= rate ratio
Abdominal pain, Anorexia, Dyspepsia, Gastrointestinal, Gastroesophageal Reflux Disorder, Heartburn
Abnormal Accommodation, Dry Eyes, Blurred Vision, Treatment-related Glaucoma, Visual Disturbance
Back Pain, Muscle Spasms, Pain in Extremity
Atrial Fibrillation, Cardiovascular Disease Adverse Event, Hypertension, Palpitations,
Balance Disorder, Dizziness, Falls, Vertigo
Bronchitis, Cough, Influenza, Upper Respiratory Tract Infection
Cognitive Adverse Events, Confusional State, Memory Impairment, Nervous System Adverse Event, Nervousness, Somnolence
Nasal Dryness, Nasopharyngitis, Sinusitis,